Bristol-Myers Squibb Company (BMY) Covered Calls

Bristol-Myers Squibb Company covered calls Bristol-Myers Squibb Company is a global biopharmaceutical leader focused on discovering and delivering innovative medicines for serious diseases. The company specializes in high-impact therapeutic areas including oncology, hematology, immunology, cardiovascular, and neuroscience. Its portfolio features industry-leading treatments for various cancers and inflammatory conditions, supported by a pipeline of cell therapies and advanced biopharmaceutical solutions.

You can sell covered calls on Bristol-Myers Squibb Company to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BMY (prices last updated Fri 4:16 PM ET):

Bristol-Myers Squibb Company (BMY) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
60.74 +0.88 60.68 60.95 10.8M - 122
Covered Calls For Bristol-Myers Squibb Company (BMY)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 61 0.51 60.44 0.8% 36.5%
Mar 20 60 2.31 58.64 2.3% 23.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Bristol-Myers Squibb Company (BMY) is a premier global biopharmaceutical firm that has pivoted from a traditional diversified manufacturer into a research-driven leader focused on specialty medicines. The company operates at the intersection of biotechnology and traditional pharmaceuticals, leveraging advanced scientific platforms to address significant unmet medical needs across a variety of chronic and life-threatening conditions.

Core Business and Products

  1. Oncology and Hematology: This is a cornerstone of the company’s revenue and research. Key products include Opdivo, a blockbuster immunotherapy used for various cancers, and Pomalyst/Imnovid for multiple myeloma. The company has also become a leader in cell therapy through its CAR-T platforms, which provide personalized treatments for aggressive blood cancers.
  2. Cardiovascular: The company maintains a leading position in this sector with Eliquis, an oral anticoagulant developed in partnership with other industry leaders. This medication is one of the most widely prescribed blood thinners globally for stroke prevention and deep vein thrombosis.
  3. Immunology and Neuroscience: This segment includes treatments like Orencia for rheumatoid arthritis and newer entries into the neurological disorder markets. The recent acquisition of specialized biotech firms has expanded the company’s presence in neuropsychiatry and inflammatory diseases.

Competitive Landscape

The biopharmaceutical industry is characterized by intense competition and rapid technological change. In the oncology and immunology sectors, the company faces significant competition from Merck and AstraZeneca. In the cardiovascular and general medicine markets, major rivals include Pfizer and AbbVie. Additionally, the company competes with large-cap innovators like Eli Lilly and Amgen for talent, laboratory space, and market share in the emerging cell and gene therapy fields.

Strategic Outlook and Innovation

The company is executing a transition strategy aimed at replacing revenue from legacy products as they face generic competition. This strategy relies on a wave of recent approvals and a late-stage pipeline rich in antibody-drug conjugates, radiopharmaceuticals, and targeted protein degradation platforms. Management is prioritizing the development of transformational medicines that offer significant differentiation over existing standards of care. A key area of innovation is the expansion of cell therapy into solid tumors and autoimmune diseases, moving beyond its initial success in blood cancers. To support these goals, the company continues to engage in strategic acquisitions and collaborations with smaller biotechnology firms to access novel modalities and early-stage scientific breakthroughs. The focus remains on maintaining a durable, high-margin portfolio through disciplined research and development and operational efficiency.